Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar

In this article

Eli Lilly

on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars.

The pharmaceutical giant anticipates its 2026 revenue will come in between $80 billion and $83 billion. Analysts expected revenue of $77.62 billion, according to LSEG.

Lilly also expected adjusted earnings to be between $33.50 and $35 per share for the year. That compares with analysts’ estimate of $33.23 per share, according to LSEG.